EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Ducournau, P. [1 ]
Latimer, N. [2 ]
Sabate, E. [1 ]
Walzer, S. [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[2] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66575-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A471 / A472
页数：2
相关论文
共 50 条
  • [21] FOLFOX-4 REGIMEN AS ADJUVANT TREATMENT OF RADICALLY RESECATED GASTRIC CANCER PATIENTS
    Lucia, Cannella
    Alfonso, De Stefano
    Antonella, Prudente
    Carolina, Cimminiello
    Elide, Matano
    Roberto, Bianco
    Chiara, Carlomagno
    Anna, Crispo
    Sabino, De Placido
    ANNALS OF ONCOLOGY, 2009, 20
  • [22] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the US
    Aballea, S
    Chancellor, J
    Raikou, M
    Drummond, M
    Weinstein, M
    Jourdan, S
    Carita, P
    Bridgewater, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 254S - 254S
  • [23] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in Germany
    Aballea, S.
    Frick, M.
    Diel, R.
    Rosenfeld, S.
    Huppertz, E.
    Sievert, M.
    Jourdan, S.
    Drummond, M.
    Weinstein, M. C.
    Reichardt, P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 182 - 183
  • [24] Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin
    Petrioli, Roberto
    Pascucci, Alessandra
    Francini, Edoardo
    Marsili, Stefania
    Sciandivasci, Angela
    Tassi, Rossana
    Civitelli, Serenella
    Tanzini, Gabriello
    Lorenzi, Marco
    Francini, Guido
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 105 - 111
  • [25] Efficacy and tolerability of adjuvant modified FOLFOX-4 following chemoradioterapy for stage III rectum adenocarcinoma.
    Cihan, S.
    Uncu, D.
    Babacan, N. A.
    Odabas, H.
    Ozdemir, N.
    Oksuzoglu, O. B.
    Zengin, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin
    Roberto Petrioli
    Alessandra Pascucci
    Edoardo Francini
    Stefania Marsili
    Angela Sciandivasci
    Rossana Tassi
    Serenella Civitelli
    Gabriello Tanzini
    Marco Lorenzi
    Guido Francini
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 105 - 111
  • [27] Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer
    Ho, Maria Y.
    Chang, Albert Y.
    Ruan, Jenny Y.
    Cheung, Winson Y.
    CLINICAL COLORECTAL CANCER, 2016, 15 (02) : 158 - 163
  • [28] Bevacizumab and cetuximab in adjuvant for colon cancer stage III: why such a failure in an adjuvant situation?
    Andre, Thierry
    Larsen, Annette K.
    de Gramont, Aimery
    BULLETIN DU CANCER, 2012, 99 (06) : 607 - 608
  • [29] A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC): A UK PERSPECTIVE
    Ducournau, P.
    Lewis, G.
    McDonald, A.
    Millar, D. R.
    Sabate, E.
    Walzer, S.
    VALUE IN HEALTH, 2008, 11 (06) : A472 - A473
  • [30] ECONOMIC EVALUATION OF XELOX VS FOLFOX4 AS ADJUVANT TREATMENT FOR PATIENTS WITH STAGE III COLON CANCER IN SOUTH KOREA
    Kim, C. M.
    Ju, S. Y.
    Kim, S. H.
    Kang, M.
    Park, J.
    Choi, W. S.
    VALUE IN HEALTH, 2011, 14 (07) : A469 - A469
12345